Breaking News Instant updates and real-time market news.

QURE

uniQure

$75.86

0.34 (0.45%)

07:01
07/08/19
07/08
07:01
07/08/19
07:01

uniQure price target raised to $94 from $81 at Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros raised his price target for uniQure to $94 from $81 after the company over the weekend presented nine-month data from the Phase 2b trial of AMT-061 in hemophilia B. The analyst remains optimistic that uniQure has the "best-in-class" hemophilia B gene therapy product. Further, he thinks new interest could emerge from the company's pipeline beyond hemophilia B this year. Piros reiterates an Overweight rating on uniQure shares.

  • 30

    Jul

  • 09

    Sep

QURE uniQure
$75.86

0.34 (0.45%)

05/07/19
RHCO
05/07/19
NO CHANGE
Target $76
RHCO
Buy
uniQure price target raised to $76 from $64 at SunTrust
SunTrust analyst Edward Nash raised his price target on uniQure to $76 after the company disclosed plans last week to present 24-week data from its ongoing Phase IIb study of AMT-061 in hemophilia B on May 10th . The analyst believes that the pre-clinical data should provide "additional validation" to uniQure's "technology platform and research engine," keeping his Buy rating on the shares.
05/12/19
PIPR
05/12/19
NO CHANGE
Target $80
PIPR
Overweight
uniQure's AMT-061 looking 'clearly superior' to competition, says Piper Jaffray
Piper Jaffray analyst Danielle Brill notes that uniQure reported that the three patients in its Phase 2b trial for hemophilia-B gene therapy - AMT-061 - had an average Factor IX activity of 47% of the normal at 26 weeks. Considering that the average FIX activity was 38% of the normal at 12 weeks in the last update provided, the analyst finds these results "highly encouraging" and indicative of a durable and effective therapy that is producing stronger responses than previous competitors. Brill believes these results bode well for AMT-061's pivotal Phase 3 trial, which is recruiting right now, with topline data expected by year end 2020. Overall, the analyst says the company's AMT-061 is looking "clearly superior" to competition in Phase 2b Hemo-B update, and reiterates an Overweight rating and $80 price target on the shares.
05/16/19
CHDN
05/16/19
NO CHANGE
Target $175
CHDN
Buy
uniQure jumps after Chardan boosts price target to $175 from $100
Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease. The stock in morning trading is up 4.5%, or $2.63, to $61.64. uniQure, a Chardan Top Pick for 2019, could be headed towards a $5B-$10B valuation as support emerges for what could be a "best-in-class, breakthrough" Huntington's disease franchise, Amusa tells investors in a research note. In the second half of 2019, uniQure is expected to make AMT-130 the first one-time gene theraphy to enter the clinic for Huntington's, the analyst adds. Following due diligence, Amusa now expects peak AMT-130 sales of $2.7B, 25% risk-adjusted, in 2026. While the market opportunity for Huntington's is potentially larger than that for Duchenne muscular dystrophy, uniQure does have some analogy to Sarepta Therapeutics (SRPT), which moved up 114% in 2018, Amusa writes. He keeps a Buy rating on uniQure shares.
06/11/19
JANY
06/11/19
NO CHANGE
JANY
Buy
uniQure weakness a buying opportunity, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong said he does not see any fundamental reason for today's weakness in shares of uniQure (QURE), attributing the pullback as likely due to profit taking following some recent strong performance. Roche's (RHHBY) deal to buy Spark Therapeutics (ONCE) in February had a positive impact on the overall gene therapy sector and investor speculation has contributed to an over 30% increase in uniQure shares over the past two weeks, noted Zhong, who said his valuation does not include any acquisition assumption or premium. The analyst, who sees uniQure having the first FDA approval for an AAV gene therapy for hemophilia B and the first AAV gene therapy program in the clinic for Huntington's disease, keeps a Buy rating on the stock and would be a buyer amid today's weakness.

TODAY'S FREE FLY STORIES

SSRM

SSR Mining

$14.72

0.665 (4.73%)

12:25
07/17/19
07/17
12:25
07/17/19
12:25
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
07/17/19
07/17
12:25
07/17/19
12:25
General news
Treasury Action: the downdraft in European rates has helped pulling Treasury yields lower »

Treasury Action: the…

CAPR

Capricor Therapeutics

$6.39

0.48 (8.12%)

12:25
07/17/19
07/17
12:25
07/17/19
12:25
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

IBM

IBM

$142.94

-0.6 (-0.42%)

12:24
07/17/19
07/17
12:24
07/17/19
12:24
Earnings
Fly Intel: What to watch in IBM's earnings report »

IBM (IBM) is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

AMZN

Amazon.com

$1,999.39

-10.61 (-0.53%)

, QCOM

Qualcomm

$76.74

1.08 (1.43%)

12:23
07/17/19
07/17
12:23
07/17/19
12:23
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have dropped in…

AMZN

Amazon.com

$1,999.39

-10.61 (-0.53%)

QCOM

Qualcomm

$76.74

1.08 (1.43%)

MSFT

Microsoft

$137.11

0.03 (0.02%)

T

AT&T

$33.47

-0.1 (-0.30%)

BAC

Bank of America

$29.47

0.475 (1.64%)

CSX

CSX

$71.11

-8.46 (-10.63%)

ABT

Abbott

$86.33

3.22 (3.87%)

SGEN

Seattle Genetics

$73.43

10.31 (16.33%)

INO

Inovio

$2.65

-0.35 (-11.67%)

NUS

Nu Skin

$37.95

-7.55 (-16.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 06

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 09

    Sep

  • 13

    Nov

KSU

Kansas City Southern

$118.05

-4.78 (-3.89%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 13

    Nov

NSC

Norfolk Southern

$194.90

-11.63 (-5.63%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
Norfolk Southern rating change  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Aug

CSX

CSX

$71.21

-8.36 (-10.51%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
CSX rating change  »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 13

    Nov

UNP

Union Pacific

$166.50

-8.6 (-4.91%)

12:17
07/17/19
07/17
12:17
07/17/19
12:17
Downgrade
Union Pacific rating change  »

Union Pacific downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
07/17/19
07/17
12:17
07/17/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
07/17/19
07/17
12:16
07/17/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$59.31

0.36 (0.61%)

12:15
07/17/19
07/17
12:15
07/17/19
12:15
Options
NetApp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
07/17/19
07/17
12:15
07/17/19
12:15
General news
Breaking General news story  »

Kansas City Federal…

CBB

Cincinnati Bell

$4.28

-0.44 (-9.32%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Cincinnati Bell falls -9.5% »

Cincinnati Bell is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$21.02

-2.08 (-9.00%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -9.0% »

Direxion Daily Junior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$38.13

-7.37 (-16.20%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Nu Skin falls -16.0% »

Nu Skin is down -16.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

AG

First Majestic

$9.10

0.53 (6.18%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
First Majestic rises 6.2% »

First Majestic is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$70.17

5.71 (8.86%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 8.7% »

Direxion Daily Jr Gld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSM

Fortuna Silver Mines

$3.55

0.37 (11.65%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Fortuna Silver Mines rises 11.6% »

Fortuna Silver Mines is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
07/17/19
07/17
11:55
07/17/19
11:55
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

11:55
07/17/19
07/17
11:55
07/17/19
11:55
Conference/Events
Federal Reserve Bank of Kansas City to speak on economic outlook »

Kansas City Federal…

AVXL

Anavex

$3.03

(0.00%)

11:52
07/17/19
07/17
11:52
07/17/19
11:52
Hot Stocks
Anavex presents new clinical data identifying gut microbiota biomarkers »

Anavex Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.90

-0.01 (-0.08%)

11:50
07/17/19
07/17
11:50
07/17/19
11:50
Options
Call block in Caesar's noted as account swap from July 8th opener »

Call block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$17.95

-0.48 (-2.60%)

11:45
07/17/19
07/17
11:45
07/17/19
11:45
Options
Mylan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

NTDOY

Nintendo

$0.00

(0.00%)

11:43
07/17/19
07/17
11:43
07/17/19
11:43
Periodicals
Nintendo to launch new Switch model with improved battery life, Kotaku says »

Nintendo plans to release…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.